Your browser doesn't support javascript.
loading
Integrating Protein Interaction Surface Prediction with a Fragment-Based Drug Design: Automatic Design of New Leads with Fragments on Energy Surfaces.
Torielli, Luca; Serapian, Stefano A; Mussolin, Lara; Moroni, Elisabetta; Colombo, Giorgio.
Afiliação
  • Torielli L; Department of Chemistry, University of Pavia, Via Taramelli 12, Pavia27100, Italy.
  • Serapian SA; Department of Chemistry, University of Pavia, Via Taramelli 12, Pavia27100, Italy.
  • Mussolin L; Department of Woman's and Child's Health, Pediatric Hematology, Oncology and Stem Cell Transplant Center, University of Padua, Via Giustiniani, 3, Padua35128, Italy.
  • Moroni E; Istituto di Ricerca Pediatrica Città della Speranza, Corso Stati Uniti, 4 F, Padova35127, Italy.
  • Colombo G; SCITEC-CNR, via Mario Bianco 9, Milano20131, Italy.
J Chem Inf Model ; 63(1): 343-353, 2023 01 09.
Article em En | MEDLINE | ID: mdl-36574607
ABSTRACT
Protein-protein interactions (PPIs) have emerged in the past years as significant pharmacological targets in the development of new therapeutics due to their key roles in determining pathological pathways. Herein, we present fragments on energy surfaces, a simple and general design strategy that integrates the analysis of the dynamic and energetic signatures of proteins to unveil the substructures involved in PPIs, with docking, selection, and combination of drug-like fragments to generate new PPI inhibitor candidates. Specifically, structural representatives of the target protein are used as inputs for the blind physics-based prediction of potential protein interaction surfaces using the matrix of low coupling energy decomposition method. The predicted interaction surfaces are subdivided into overlapping windows that are used as templates to direct the docking and combination of fragments representative of moieties typically found in active drugs. This protocol is then applied and validated using structurally diverse, important PPI targets as test systems. We demonstrate that our approach facilitates the exploration of the molecular diversity space of potential ligands, with no requirement of prior information on the location and properties of interaction surfaces or on the structures of potential lead compounds. Importantly, the hit molecules that emerge from our ab initio design share high chemical similarity with experimentally tested active PPI inhibitors. We propose that the protocol we describe here represents a valuable means of generating initial leads against difficult targets for further development and refinement.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Proteínas de Membrana Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Chem Inf Model Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Proteínas de Membrana Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Chem Inf Model Ano de publicação: 2023 Tipo de documento: Article